Aclaris Therapeutics, Inc. (ACRS) Issues Earnings Results, Beats Expectations By $0.12 EPS

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) released its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.56) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.68) by $0.12, Bloomberg Earnings reports.

Shares of Aclaris Therapeutics (ACRS) traded down 1.19% on Friday, reaching $24.96. The company’s stock had a trading volume of 264,652 shares. The stock’s market cap is $667.33 million. The firm has a 50 day moving average price of $27.65 and a 200-day moving average price of $27.92. Aclaris Therapeutics has a 12-month low of $19.75 and a 12-month high of $33.25.

TRADEMARK VIOLATION WARNING: “Aclaris Therapeutics, Inc. (ACRS) Issues Earnings Results, Beats Expectations By $0.12 EPS” was originally posted by BNB Daily and is owned by of BNB Daily. If you are accessing this piece on another domain, it was stolen and republished in violation of United States and international copyright laws. The correct version of this piece can be viewed at https://www.baseball-news-blog.com/2017/08/19/aclaris-therapeutics-inc-acrs-announces-quarterly-earnings-results-updated.html.

A number of research analysts have weighed in on ACRS shares. BidaskClub lowered Aclaris Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. Cantor Fitzgerald set a $50.00 target price on Aclaris Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, August 9th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $36.00 target price on shares of Aclaris Therapeutics in a research note on Monday, July 31st. ValuEngine upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, June 15th. Finally, Guggenheim reiterated a “buy” rating and issued a $40.00 price objective on shares of Aclaris Therapeutics in a research report on Tuesday, July 4th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $39.00.

In related news, Director Andrew N. Schiff acquired 108,601 shares of the business’s stock in a transaction that occurred on Wednesday, August 16th. The stock was purchased at an average cost of $23.02 per share, for a total transaction of $2,499,995.02. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 16.30% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Citigroup Inc. increased its position in shares of Aclaris Therapeutics by 171.8% in the second quarter. Citigroup Inc. now owns 4,313 shares of the biotechnology company’s stock valued at $117,000 after buying an additional 2,726 shares during the period. UBS Group AG increased its position in shares of Aclaris Therapeutics by 60.4% in the first quarter. UBS Group AG now owns 4,462 shares of the biotechnology company’s stock valued at $133,000 after buying an additional 1,681 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Aclaris Therapeutics by 269.0% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,801 shares of the biotechnology company’s stock worth $143,000 after buying an additional 3,500 shares during the last quarter. Legal & General Group Plc increased its stake in Aclaris Therapeutics by 98.3% in the second quarter. Legal & General Group Plc now owns 5,254 shares of the biotechnology company’s stock worth $142,000 after buying an additional 2,605 shares during the last quarter. Finally, First Mercantile Trust Co. increased its stake in Aclaris Therapeutics by 11.2% in the first quarter. First Mercantile Trust Co. now owns 5,945 shares of the biotechnology company’s stock worth $177,000 after buying an additional 600 shares during the last quarter. Hedge funds and other institutional investors own 88.71% of the company’s stock.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Earnings History for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply